US drug giant Merck drops out the COVID-19 vaccine race, after its 2 vaccine candidates failed to generate a strong immune response
- US pharmaceutical giant
Mercksaid Monday that it has stopped developing two potential COVID-19 vaccines.
- The vaccines were well tolerated in clinical trials, but failed to produce an adequate immune response.
- The company said it will focus resources on two experimental treatments for COVID-19 instead.
US pharma giant Merck has scrapped two coronavirus
View all Offers
Dettol Original Germ Protection Bathing Soap bar, 125 gm, Buy 4 Get 1 Free₹ 220Buy On
Dettol Original Germ Protection Liquid Handwash Refill, 1500ml (Price Off)₹ 208Buy On
Mamaearth Onion Hair Fall Shampoo for Hair Growth & Hair Fall Control, with Onion Oil & Plant Keratin 250ml₹ 349Buy On
- 30% OFF
Pampers All round Protection Pants, Large size baby diapers (LG) 64 Count, Anti Rash diapers, Lotion with Aloe Vera₹ 801₹ 1149Buy On
- 6% OFF
Parachute jumbo pack 100% pure coconut oil 600 ml (bottle )₹ 236₹ 250Buy On
Merck said it would now focus on advancing two experimental treatments for COVID-19 that are in late stage development."In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets," Kartsonis told the Wall Street Journal.
Merck is a $190-billion company, with one of the largest vaccine businesses in the world. It entered the vaccine race in May 2020, hoping to build on its success developing the first US-approved Ebola vaccine.V590, one of Merck's COVID-19 shots, mimicked technology from the Ebola shot, using a weakened virus to trigger the immune response. Its other experimental shot, V591, was based on a measles vaccine. Both COVID-19 candidates would have been single shots. Merck and IAVI, the vaccine co-developer for V590, had said they would make it affordable and accessible globally.
Merck's approach to vaccine development was different to Moderna's and Pfizer's, the companies that have two-dose vaccines currently authorized in the US, who utilized mRNA technology - a genetic code that triggers the immune system.
Merck said it anticipated trial results for its novel COVID-19 drugs in the coming weeks, and could ask US regulators to fast-track emergency authorization if results are positive.Kartosonis said that one of the experimental treatments, MK-7110, could reach sick patients by the middle of the year. The US government under President Donald Trump agreed to pay Merck up to $365 million for 60,000 to 100,000 doses of MK-7110 until June 30.
Having effective COVID-19 treatments remains important, especially as new variants emerge that may be able to thwart vaccines, Kartsonis said.
- Weekend watch list for OTT — Fahadh Faasil’s Malik to Farhan Akhtar’s Toofan and more
- Reliance Retail surprises all by more than doubling its net profit in the last three months
- Reliance Jio adds 42 million subscribers but the average revenue is pretty much the same
- YES Bank’s net profit grows four fold as provision for bad loans shrink
- Amazon Prime Day 2021: Best deals and offers on headphones